$12.80 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter
Wall Street brokerages expect that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will post $12.80 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The highest sales estimate is $19.25 million and the lowest is $3.00 million. The firm is expected to report its next earnings results on Tuesday, November 14th.
On average, analysts expect that Conatus Pharmaceuticals will report full-year sales of $12.80 million for the current year, with estimates ranging from $38.80 million to $54.16 million. For the next fiscal year, analysts anticipate that the company will report sales of $56.65 million per share, with estimates ranging from $4.00 million to $117.80 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $9.33 million. During the same quarter last year, the firm posted ($0.30) EPS.
CNAT has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Seaport Global Securities reiterated a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $16.17.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 5.53 on Wednesday. Conatus Pharmaceuticals has a 52 week low of $1.45 and a 52 week high of $9.40. The stock has a 50 day moving average price of $5.57 and a 200 day moving average price of $5.85. The company’s market cap is $165.92 million.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNAT. Nationwide Fund Advisors purchased a new stake in Conatus Pharmaceuticals during the first quarter valued at about $413,000. Bank of New York Mellon Corp raised its position in Conatus Pharmaceuticals by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 1,655 shares in the last quarter. Renaissance Technologies LLC raised its position in Conatus Pharmaceuticals by 28.1% during the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after purchasing an additional 51,590 shares in the last quarter. Courage Capital Management LLC raised its position in Conatus Pharmaceuticals by 25.0% during the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in Conatus Pharmaceuticals during the second quarter valued at about $109,000. Institutional investors and hedge funds own 33.13% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.